Chronic kidney disease (CKD)
eGFR-staged considerations across the peptide library — renal clearance, dose adjustment, dialysis-specific monitoring. Affects ~14% of US adults.
What changes during this transition
Chronic kidney disease intersects with peptide therapeutics in two opposing ways. First, the standard-of-care toolkit for CKD has expanded dramatically — semaglutide's FLOW trial (Perkovic et al., NEJM 2024, n=3,533) demonstrated a 24% reduction in major kidney events in T2D-CKD, making it the first GLP-1 with hard renal-outcome evidence and earning specific guideline endorsement (ADA 2025, KDIGO 2024). Tirzepatide's renal program is following with secondary-endpoint signals from SURPASS-4. So some peptides in this library are now mainstream nephrology medicine for the right patient. Second, many peptides marketed for adjacent indications carry CKD-specific risks that the community framing rarely addresses — renal clearance, dose-adjustment thresholds, dehydration risk from GI side effects, and the catabolic-CKD interaction with weight-loss agents all matter. Several peptides have essentially no human renal-PK data at all (BPC-157 is the canonical example), making CKD use a leap not backed by published pharmacology. Staging matters: CKD 1-2 is usually clinically silent and rarely changes peptide protocols; CKD 3a (eGFR 45-59) is the inflection where most adjustments begin; CKD 4-5 requires nephrology co-management for nearly any prescription decision. Dialysis adds another layer — water-soluble compounds (B12, certain peptides) are removed by hemodialysis and need replacement.
Important caveat
CKD changes the calculation for nearly every peptide. If you have eGFR <60, coordinate any peptide protocol with your nephrologist BEFORE starting — not as a courtesy, but because dose adjustments and contraindications exist. Late-stage CKD (eGFR <30), dialysis, and post-transplant are not DIY contexts. GLP-1 agonists in particular can precipitate AKI through dehydration; this is a documented mechanism, not a theoretical one. Transplant recipients are a separate conversation — immunosuppressed, with their own drug-interaction matrix.
Peptides editorially relevant to chronic kidney disease (ckd)
3 peptides from the library — each evidence-tiered honestly.
- SemaglutideTier 1
GLP-1 receptor agonist
The most-studied GLP-1 agonist in modern medicine, with Tier 1 evidence for diabetes, weight loss, and major adverse cardiovascular events.
- TirzepatideTier 1
GLP-1 / GIP dual agonist
FDA-approved dual incretin agonist with the strongest weight-loss and glycemic data in this library.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.